Evidence map›Paper›PMID 41057423›Full record

ArticleScientific reports2025

Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma.

Olivier Caliez, Mathilde Wagner, Valérie Taly, Léo Mas, Solène Doat, Daniel Pietrasz, Pierre Laurent-Puig, Jean-Baptiste Bachet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Olivier CaliezDepartment of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France. olivier.caliez@chicreteil.fr.
Mathilde WagnerDepartment of Radiology, Groupe Hospitalier Pitié Salpêtrière, Sorbonne University, Paris, France.
Valérie TalyCentre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, USPC, Université de Paris, Sorbonne University, Paris, France.
Léo MasDepartment of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
Solène DoatDepartment of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
Daniel PietraszCentre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, USPC, Université de Paris, Sorbonne University, Paris, France.
Pierre Laurent-PuigCentre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, USPC, Université de Paris, Sorbonne University, Paris, France.
Jean-Baptiste BachetDepartment of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France. jean-baptiste.bachet@aphp.fr.

Funding

Fondation pour la Recherche Médicale M2R201806006018
6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA) is a promising marker with a strong prognostic value in metastatic pancreatic ductal adenocarcinoma (mPDAC). However, ctDNA is not detected in about a third of patients with mPDAC. The objective of this study was to assess the correlation between ctDNA and tumor volume (TV). In this monocentric cohort of mPDAC patients naïve for chemotherapy, ctDNA quantity at baseline (before chemotherapy initiation) was assessed by droplet-based digital PCR targeting two methylated markers (HOXD8 and POU4F1). TV was measured in 3D, for the primary lesion and the metastatic sites, from baseline thoraco-abdomino-pelvic computed tomography (CT) scan. Among the 71 included patients, ctDNA was detected in 47 patients (66.2%). There was a significant correlation of total and liver TV with ctDNA quantity, with Spearman's ρ of 0.353 (p = 0.01) and 0.500 (p < 0.001), respectively. Total and liver TV were higher in patients with detected ctDNA (129.5 vs. 31.8 mL, p = 0.002 and 18 vs. 1 mL, p < 0.001, respectively). Total and liver TV thresholds of 90.1 and 3.7 mL were associated with ctDNA detection, respectively. In conclusion, this study demonstrates, in patients with mPDAC, a moderate correlation between ctDNA and TV in mPDAC, especially for liver metastases TV.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalCirculating Tumor DNADNA MethylationPancreatic NeoplasmsAdultAgedFemaleHomeodomain ProteinsHumansMaleMiddle AgedNeoplasm MetastasisPrognosisTumor BurdenBiomarkers, TumorCirculating Tumor DNAHomeodomain ProteinsCancer imagingCirculating tumor DNAMetastatic pancreatic adenocarcinomaTumor biomarkersTumor volume

Identifiers

PMID41057423
PMCPMC12504583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.